Lexaria Bioscience Corp. received a USD$2.6 million (AUD$3.67 million) cash rebate from the Australian Tax Office for its 2025 human study conducted in Australia. This rebate, part of the Australian R&D Tax Incentive Program, was awarded after verifying compliance and will support Lexaria's future research and development efforts in Australia. The funds were received without issuing new equity, thus avoiding shareholder dilution, and will be reflected in the company’s upcoming financial filings. Lexaria plans to announce its 2027 R&D initiatives utilizing these funds to further validate its DehydraTECH drug delivery technology.
Citizens Financial Group (CFG) reported robust second-quarter 2026 results, including 14% growth in net interest income and 35% growth in net income. The bank is on track to meet its 16-18% target for return on tangible common equity (ROTCE), achievi...
Victory Square Technologies reported a 421% year-over-year revenue increase to $28 million in Q2 2026, mainly due to the strong performance of its subsidiary Hydreight Technologies in U.S. healthcare infrastructure. Net income rose to $2.5 million fr...
Blue Owl Capital Corp. is rated a 'Strong Buy' due to its diversified $15 billion portfolio, which is mostly senior-secured and shows strong credit quality with low risk and conservative leverage. Its adjusted net investment income per share of $0.34...
374Water Inc will present its AirSCWO supercritical water oxidation technology at WEFTEC 2026 in New Orleans from September 28-30. This technology permanently destroys PFAS, biosolids, and other organic wastes by reducing waste volume and recovering ...
Alphabet CEO Sundar Pichai revealed that the company is facing challenges in rapidly expanding its AI capacity to meet demand. Meanwhile, competitor Anthropic has successfully secured 5 gigawatts of AI computing power, highlighting a significant deve...
